Carolyn Dolores Britten MD
Gastrointestinal Cancer, Hematologic Oncology
Director, Division of Hematology/Oncology Associate Professor at Medical University of South Carolina
Join to view full profile
171 Ashley AveCharleston, SC 29425
Phone+1 843-792-1414
Fax+1 843-792-1190
Dr. Britten is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Toronto Faculty of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 2001 - 2028
SC State Medical License 2012 - 2027
TX State Medical License 1997 - 2009
American Board of Internal Medicine Medical Oncology
Royal College of Physicians and Surgeons of CanadaInternal Medicine- Royal College of Physicians and Surgeons of CanadaMedical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
- Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
- Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction
- Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Publications & Presentations
PubMed
- 8 citationsClinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.James H Lewis, Sophia K Khaldoyanidi, Carolyn D Britten, Andrew H Wei, Marion Subklewe
American Journal of Clinical Oncology. 2022-08-01 - 28 citationsA phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.Christian Kollmannsberger, Carolyn D. Britten, Anthony J. Olszanski, Joan Andrews Walker, Wei Zang
Investigational New Drugs. 2021-07-15 - 3 citationsThe effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.Darcy B. Pooler, Dylan B. Ness, John Sarantopoulos, Nicholas Squittieri, Shoba Ravichandran
British Journal of Clinical Pharmacology. 2021-03-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
